+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Sexually Transmitted Diseases Testing Market By Disease Type, By the Location of Testing Testing, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • PDF Icon

    Report

  • 93 Pages
  • January 2022
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5553073
The Latin America, Middle East and Africa Sexually Transmitted Diseases (STD) Testing Market is expected to witness market growth of 6.7% CAGR during the forecast period (2021-2027).

The demand for STD testing is predicted to increase as a result of recommendations from various regulatory bodies for annual STD screening for sexually active men and women. STD screening services are now widely covered by health-care plans, which is expected to likely boost the worldwide STD testing market's growth. For example, under the Affordable Care Act in the United States, STD screening treatments are covered without cost-sharing. STD prevention and control techniques have been specified by regulatory bodies like the World Health Organization.

The prevalence of STDs or STIs are gaining a high momentum in the African region, which is leading to various health problems and serious complications. When compared to other regions, Sub-Saharan Africa has the highest annual STD cases. Infections with the herpes simplex virus and the human papillomavirus are becoming more common in Sub-Saharan Africa. While there are more than 20 bacteria that cause STDs, they mostly manifest themselves in four syndromes and can thus be treated syndromically. Many government and major healthcare organizations are working together to improve the state of medical services, especially STD treatment across this region.

The Brazil market dominated the LAMEA Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $2.48 billion by 2027. The Argentina market is poised to grow at a CAGR of 7.3% during (2021 - 2027). Additionally, The UAE market is expected to showcase CAGR of 6.4% during (2021 - 2027).

Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.

Scope of the Study


Market Segments Covered in the Report:


By Disease Type

  • Chlamydia
  • Herpes simplex
  • Gonorrhea
  • Syphilis 
  • Human papillomavirus (HPV)
  • Other Disease

By Location of Testing

  • Laboratory Testing
  • Point of care (POC) Testing

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Sexually Transmitted Diseases (STD) Testing Market, by Disease Type
1.4.2 LAMEA Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing
1.4.3 LAMEA Sexually Transmitted Diseases (STD) Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions 2019, Oct - 2021, Dec) Leading Players
Chapter 4. LAMEA Sexually Transmitted Diseases (STD) Testing Market by Disease Type
4.1 LAMEA Chlamydia Market by Country
4.2 LAMEA Herpes simplex virus Market by Country
4.3 LAMEA Gonorrhea Market by Country
4.4 LAMEA Syphilis Market by Country
4.5 LAMEA Human papillomavirus (HPV) Market by Country
4.6 LAMEA Other Disease Market by Country
Chapter 5. LAMEA Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
5.1 LAMEA Laboratory Testing Market by Country
5.2 LAMEA Point of care (POC) Testing Market by Country
Chapter 6. LAMEA Sexually Transmitted Diseases (STD) Testing Market by Country
6.1 Brazil Sexually Transmitted Diseases (STD) Testing Market
6.1.1 Brazil Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.1.2 Brazil Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.2 Argentina Sexually Transmitted Diseases (STD) Testing Market
6.2.1 Argentina Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.2.2 Argentina Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.3 UAE Sexually Transmitted Diseases (STD) Testing Market
6.3.1 UAE Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.3.2 UAE Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.4 Saudi Arabia Sexually Transmitted Diseases (STD) Testing Market
6.4.1 Saudi Arabia Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.4.2 Saudi Arabia Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.5 South Africa Sexually Transmitted Diseases (STD) Testing Market
6.5.1 South Africa Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.5.2 South Africa Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.6 Nigeria Sexually Transmitted Diseases (STD) Testing Market
6.6.1 Nigeria Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.6.2 Nigeria Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.7 Rest of LAMEA Sexually Transmitted Diseases (STD) Testing Market
6.7.1 Rest of LAMEA Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.7.2 Rest of LAMEA Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
Chapter 7. Company Profiles
7.1 BioMérieux S.A.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Abbott Laboratories
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments
7.2.5.1 Approvals and Trials
7.3 Becton, Dickinson and Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments
7.3.5.1 Product Launches and Product Expansions
7.4 Hologic, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments
7.4.5.1 Approvals and Trials
7.4.5.2 Product Launches and Product Expansions
7.4.5.3 Acquisition and Mergers:
7.5 Thermo Fisher Scientific, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments
7.5.5.1 Partnerships, Collaborations, and Agreements
7.5.6 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments
7.6.5.1 Partnerships, Collaborations, and Agreements
7.6.5.2 Product Launches and Product Expansions
7.7 DiaSorin Molecular LLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Danaher Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bio-Rad laboratories, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments
7.9.5.1 Acquisition and Mergers:
7.10. OraSure Technologies, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments
7.10.5.1 Product Launches and Product Expansions
7.10.5.2 Acquisition and Mergers:

Companies Mentioned

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Methodology

Loading
LOADING...